Morning Briefing
Summaries of health policy coverage from major news organizations
Next-Gen Covid Booster Shots Expected In September
NBC News: FDA Plans To Authorize Covid Omicron Boosters Around Labor Day
The Food and Drug Administration plans to authorize updated versions of Pfizer-BioNTech’s and Moderna’s Covid boosters around Labor Day, said two people familiar with the discussions. The Biden administration is preparing to distribute the updated booster shots to teenagers and adults as part of its fall booster campaign. (Lovelace Jr., 8/24)
The Wall Street Journal: Covid-19 Booster Campaign Is Expected To Launch Next Month
The Biden administration has completed plans for a fall Covid-19 booster campaign that would launch in September with 175 million updated vaccine doses provided to states, pharmacies and other vaccination sites. The administration is procuring the doses, which drugmakers are updating to target the newest versions of the virus. The administration has also informed states, pharmacies and other entities they can begin preordering now through the end of August, according to the administration’s fall vaccination planning guide. (Armour, 8/23)
The New York Times: Biden Administration Plans For Booster Shot Campaign In September
Dr. Peter Marks, the top vaccine regulator for the Food and Drug Administration, said in an interview on Tuesday that while he could not discuss timing, his team was close to authorizing updated doses that would target the versions of the virus now circulating. Even though those formulations have not been tested in humans, he said, the agency has “extremely good” data showing that the shots are safe and will be effective. “How confident am I?” he said. “I’m extremely confident.” (LaFraniere and Weiland, 8/23)
In related news about booster shots —
The Washington Post: Your First Brush With Coronavirus Could Affect How A Fall Booster Works
When it comes to viral infections, past is prologue: The version of a virus to which we’re first exposed can dictate how we respond to later variants and, maybe, how well vaccines work. It’s a phenomenon known by the forbidding name of original antigenic sin, and, in the case of the coronavirus, it prompts a constellation of questions. Are our immune systems stuck still revving up defenses against a version of the virus that has vanished? Will updated booster shots that are designed to thwart variants be much better than the original vaccine? How often will we be reinfected? Is there a better way to broaden immunity? (Johnson, 8/23)
